TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07870889: A Randomised Active-controlled Trial to Assess the Safety and Pharmacodynamics of Two Blinded Doses of Vortosiran and Open-label Apixaban in Patients With Non-valvular Atrial Fibrillation (AF)

Sponsor: Ribocure Pharmaceuticals AB · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,905,600

Rescue Site Savings

+$4,548,400

Unlock Full NCT07870889 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07870889 Rescue Dossier →